Jonathan Aschoff
Stock Analyst at Roth Capital
(0.42)
# 4,086
Out of 4,944 analysts
44
Total ratings
21.15%
Success rate
-35.78%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTRK Ontrak | Maintains: Buy | $4 → $3 | $0.43 | +603.89% | 3 | Jul 9, 2025 | |
| GTBP GT Biopharma | Initiates: Buy | $11 | $1.68 | +554.76% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $9.43 | +122.69% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $11,100 → $5,920 | $1.91 | +309,847.64% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.48 | +1,116.22% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $5.50 | +12,881.82% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $0.74 | +2,606.36% | 1 | Jul 16, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Buy | $5,040 → $2,640 | $8.90 | +29,562.92% | 2 | May 3, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $0.67 | +5,827.68% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $4.42 | +18,904.52% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $36 | $9.97 | +261.08% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3,750 → $18,000 | $6.04 | +298,160.15% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $5.91 | +407.61% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $3.65 | +5,379.45% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $2.33 | +500.86% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7,200 → $21,600 | $2.52 | +857,042.86% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.03 | +676.70% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $3.20 | +3,025.00% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.95 | +42,005.26% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $4.88 | +678.69% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $360,000 | $4.21 | +8,550,968.88% | 1 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.70 | +5,547.06% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $2.56 | +407.81% | 1 | Dec 19, 2019 |
Ontrak
Jul 9, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.43
Upside: +603.89%
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $1.68
Upside: +554.76%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $9.43
Upside: +122.69%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $11,100 → $5,920
Current: $1.91
Upside: +309,847.64%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.48
Upside: +1,116.22%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $5.50
Upside: +12,881.82%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $0.74
Upside: +2,606.36%
Cyclacel Pharmaceuticals
May 3, 2024
Maintains: Buy
Price Target: $5,040 → $2,640
Current: $8.90
Upside: +29,562.92%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $0.67
Upside: +5,827.68%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $4.42
Upside: +18,904.52%
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $9.97
Upside: +261.08%
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $6.04
Upside: +298,160.15%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $5.91
Upside: +407.61%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $3.65
Upside: +5,379.45%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $2.33
Upside: +500.86%
Feb 14, 2023
Maintains: Buy
Price Target: $7,200 → $21,600
Current: $2.52
Upside: +857,042.86%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.03
Upside: +676.70%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $3.20
Upside: +3,025.00%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.95
Upside: +42,005.26%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $4.88
Upside: +678.69%
Feb 12, 2021
Initiates: Buy
Price Target: $360,000
Current: $4.21
Upside: +8,550,968.88%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.70
Upside: +5,547.06%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $2.56
Upside: +407.81%